Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder
NCT06029426Phase 3Completed
- Lead sponsor
- Neumora Therapeutics, Inc. (Industry)
- Enrollment
- 383 (actual)
- Start date
- 20 Sep 2023
- Primary completion
- 3 Dec 2024 (actual)
- Study completion
- 15 Jan 2025
- Last update posted
- 26 Nov 2025
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Quadruple
- Arms
- 2
Interventions
- NMRA-335140 Drug
- Placebo Drug
Conditions and primary outcome
- Major Depressive Disorder
Primary outcome
Change from Baseline to Week 6 in the Montgomery Asberg Depression Rating Scale (MADRS) total score (Baseline and up to Week 6)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT06029426.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT06029426 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.